Loading patent…
AssigneeUniversity of Maryland Biotechnology Institute
InventorsRobert C. Gallo, Joseph Bryant, Yanto Lunardi-Iskandar
Estimating the term…
The present invention relates to β-hCG, particularly β-hCG proteins having a sequence of amino acids 41-54, 45-54, 47-53, 45-57 and 45-58 and analogs and derivatives thereof. The invention further relates to methods of treatment and prevention of HIV infection by administration of a therapeutic compound of the invention. Such therapeutic compounds include hCG, β-hCG and β-hCG peptides, analogs and derivatives of hCG, β-hCG and β-hCG peptides, and nucleic acids encoding hCG, β-hCG and β-hCG peptides. In a preferred embodiment, β-hCG peptides, particularly β-hCG peptides of amino acids 47-53, 45-57 or 45-58 are administered to a subject for treatment or prevention of HIV infection in that subject. The invention also provides methods for screening hCG preparations for activity in treating or preventing HIV infection. Pharmaceutical compositions and methods of administration of Therapeutics are also provided.
An isolated peptide:
A peptide:
A peptide:
A peptide consisting essentially of β-hCG (SEQ ID NO:2) amino acid numbers 44-57 (SEQ ID NO:12) with cysteine substituted for valine at position 44, wherein:
A method of treating, or preventing the establishment of, a condition selected from the group consisting of HIV infection, Kaposi's sarcoma, and hematopoietic deficiency, in a human subject in need of such treatment or prevention, said method comprising administering to the subject an amount of a peptide:
A method of treating, or preventing the establishment of, a condition selected from the group consisting of HIV infection, Kaposi's sarcoma, and hematopoietic deficiency, in a human subject in need of such treatment or prevention, said method comprising administering to the subject an amount of a peptide:
A pharmaceutical composition comprising:
A pharmaceutical composition comprising:
A method of treating, or preventing the establishment of, a condition selected from the group consisting of HIV infection, Kaposi's sarcoma, and hematopoietic deficiency, in a human subject in need of such treatment or prevention, said method comprising administering to the subject a pharmaceutical composition comprising:
A method of treating, or preventing the establishment of, a condition selected from the group consisting of HIV infection, Kaposi's sarcoma, and hematopoietic deficiency, in a human subject in need of such treatment or prevention, said method comprising administering to the subject a pharmaceutical composition comprising:
A method for treating, or preventing the establishment of, a condition selected from the group consisting of HIV infection, Kaposi's sarcoma and hematopoietic deficiency in a human subject in need thereof comprising administering to the subject an amount of a peptide comprising an amino acid sequence consisting essentially of β-hCG (SEQ ID NO:2) amino acid numbers 45-57, and with the proviso that the peptide does not consist of the entire β-hCG (SEQ ID NO:2) chain.
A peptide consisting essentially of the amino acid sequence Leu-Gln-Gly-Val-Leu-Pro-Ala-Leu-Pro-Gln-Val-Val-Cys (SEQ ID NO:6) wherein the glycine at position 3 and the alanine at position 7 have each been replaced by Dab(Pro), where Dab(Pro) indicates a proline peptide-bonded to the amino side chain of Dab.
A peptide consisting essentially of the amino acid sequence Cys-Leu-Gln-Gly-Val-Leu-Pro-Ala-Leu-Pro-GIn-Val-Val-Cys (SEQ ID NO:26), wherein the terminal Cys residues are linked together a disulfide bond.
A peptide consisting essentially of the amino acid sequence Thr-Cys-Asp-Asp-Pro-Arg-Phe-GIn-Asp-Ser-Ser (SEQ.ID NO:7).
A peptide comprising a β-hCG (SEQ ID NO:2) segment selected from the group consisting of 41-54, 45-54, 47-53, 45-58, 41-53, 42-53, 43-53, 44-53, 44-57, 45-53, 46-53, 4-55, 45-56, 47-54, 47-56, 47-58, and 58-145 (SEQ ID NOS:
A peptide:
Dependencies are inferred from the claim text.